.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Farmers Insurance
US Department of Justice
Johnson and Johnson
Medtronic
McKesson
Covington
Cipla
Novartis
Harvard Business School

Generated: December 17, 2017

DrugPatentWatch Database Preview

MIRALUMA Drug Profile

« Back to Dashboard

When do Miraluma patents expire, and when can generic versions of Miraluma launch?

Miraluma is a drug marketed by Lantheus Medcl and is included in one NDA.

The generic ingredient in MIRALUMA is technetium tc-99m sestamibi kit. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the technetium tc-99m sestamibi kit profile page.

Summary for MIRALUMA

Drug patent expirations by year for MIRALUMA

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lantheus MedclMIRALUMAtechnetium tc-99m sestamibi kitINJECTABLE;INJECTION019785-003May 23, 1997DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: MIRALUMA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lantheus MedclMIRALUMAtechnetium tc-99m sestamibi kitINJECTABLE;INJECTION019785-003May 23, 1997► Subscribe► Subscribe
Lantheus MedclMIRALUMAtechnetium tc-99m sestamibi kitINJECTABLE;INJECTION019785-003May 23, 1997► Subscribe► Subscribe
Lantheus MedclMIRALUMAtechnetium tc-99m sestamibi kitINJECTABLE;INJECTION019785-003May 23, 1997► Subscribe► Subscribe
Lantheus MedclMIRALUMAtechnetium tc-99m sestamibi kitINJECTABLE;INJECTION019785-003May 23, 1997► Subscribe► Subscribe
Lantheus MedclMIRALUMAtechnetium tc-99m sestamibi kitINJECTABLE;INJECTION019785-003May 23, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
UBS
Colorcon
Daiichi Sankyo
Cerilliant
AstraZeneca
Federal Trade Commission
Teva
US Department of Justice
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot